Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for BioRestorative Therapies (BRTX) over the last 14 years, with Q3 2025 value amounting to $5.3 million.

  • BioRestorative Therapies' Gains from Investment Securities rose 5472.01% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 5472.01%. This contributed to the annual value of $3.3 million for FY2024, which is 12247.49% up from last year.
  • As of Q3 2025, BioRestorative Therapies' Gains from Investment Securities stood at $5.3 million, which was up 5472.01% from $5.3 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' Gains from Investment Securities registered a high of $2.4 billion during Q1 2021, and its lowest value of $25000.0 during Q1 2022.
  • Over the past 5 years, BioRestorative Therapies' median Gains from Investment Securities value was $1.5 million (recorded in 2023), while the average stood at $140.3 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 6900609.05% in 2021, then crashed by 9999.89% in 2022.
  • Over the past 5 years, BioRestorative Therapies' Gains from Investment Securities (Quarter) stood at $839639.0 in 2021, then increased by 2.98% to $864639.0 in 2022, then skyrocketed by 69.65% to $1.5 million in 2023, then soared by 122.47% to $3.3 million in 2024, then surged by 61.27% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $5.3 million for Q2 2025, and $5.2 million during Q1 2025.